Prohormones in the Early Diagnosis of Cardiac Syncope.

BACKGROUND: The early detection of cardiac syncope is challenging. We aimed to evaluate the diagnostic value of 4 novel prohormones, quantifying different neurohumoral pathways, possibly involved in the pathophysiological features of cardiac syncope: midregional-pro-A-type natriuretic peptide (MRproANP), C-terminal proendothelin 1, copeptin, and midregional-proadrenomedullin. METHODS AND RESULTS: We prospectively enrolled unselected patients presenting with syncope to the emergency department (ED) in a diagnostic multicenter study. ED probability of cardiac syncope was quantified by the treating ED physician using a visual analogue scale. Prohormones were measured in a blinded manner. Two independent cardiologists adjudicated the final diagnosis on the basis of all clinical information, including 1-year follow-up. Among 689 patients, cardiac syncope was the adjudicated final diagnosis in 125 (18%). Plasma concentrations of MRproANP, C-terminal proendothelin 1, copeptin, and midregional-proadrenomedullin were all significantly higher in patients with cardiac syncope compared with patients with other causes (P<0.001). The diagnostic accuracies for cardiac syncope, as quantified by the area under the curve, were 0.80 (95% confidence interval [CI], 0.76-0.84), 0.69 (95% CI, 0.64-0.74), 0.58 (95% CI, 0.52-0.63), and 0.68 (95% CI, 0.63-0.73), respectively. In conjunction with the ED probability (0.86; 95% CI, 0.82-0.90), MRproANP, but not the other prohormone, improved the area under the curve to 0.90 (95% CI, 0.87-0.93), which was significantly higher than for the ED probability alone (P=0.003). An algorithm to rule out cardiac syncope combining an MRproANP level of <77 pmol/L and an ED probability of <20% had a sensitivity and a negative predictive value of 99%. CONCLUSIONS: The use of MRproANP significantly improves the early detection of cardiac syncope among unselected patients presenting to the ED with syncope. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01548352.

Orientation of the Subtalar Joint: Measurement and Reliability Using Weightbearing CT Scans.

BACKGROUND: Up to 60% of patients with an osteoarthritic ankle joint develop talar tilt with progression of the osteoarthritic process. The configuration of the subtalar joint, in particular the posterior facet, may contribute to the development of this wear pattern. Recently, the subtalar vertical angle (SVA) was used to describe the posterior facet of the subtalar joint in the frontal plane. The aim of this work was to analyze if the orientation of the subtalar joint may influence the type of asymmetric ankle osteoarthritis. METHODS: In total, 60 ankles were retrospectively analyzed including 40 osteoarthritic patients and 20 healthy controls. The osteoarthritic ankles were divided into 4 groups: varus ankle joints with (incongruent) or without (congruent) a tilted talus and valgus ankle joints with (incongruent) or without (congruent) a tilted talus. The orientation of the subtalar joint was described using the SVA. The SVA was determined for every patient using weightbearing CT scans. Additionally, the inter- and intraobserver reliability was assessed using intraclass correlation coefficients (ICCs). RESULTS: The inter- and intraobserver reliability was excellent (ICC > 0.989 and >0.975, respectively). The varus groups (incongruent and congruent) had significantly lower SVA values, that is, more varus orientation of the subtalar joint than the valgus groups (P < .05). The SVA of the control group was between the values of the varus and valgus ankles. CONCLUSION: The SVA provided a reliable and consistent method to assess the varus/valgus configuration of the posterior facet of the subtalar joint. In our cohort, varus osteoarthritis of the ankle joint occurred with varus orientation of the subtalar joint whereas in patients with valgus osteoarthritis, valgus orientation of the subtalar joint was found. Our data suggest that the subtalar joint orientation may be a risk factor for the development of ankle joint osteoarthritis. LEVEL OF EVIDENCE: Level III, retrospective case control study.